SCHEMBL21577907

SCHEMBL21577907

CC(CCC(=O)NOCc1ccc(OC(=O)C(C)C)cc1)Cc1ccc(C(=O)OCc2ccc(OC(=O)C(C)C)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.41
PRSS1 P07477 4/20 0.40
TMPRSS15 P98073 4/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
PPARG P37231 1/20 0.39
FOLH1 Q04609 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20179200 0.89 FOLH1 (0.51) ELANEPRSS1TMPRSS15KMT2AMEN1
SCHEMBL21577995 0.88 HTT (0.39) PRSS1TMPRSS15KMT2AMEN1PPARG
SCHEMBL21577941 0.87 PRSS1 (0.39) ELANEPRSS1TMPRSS15KMT2AMEN1
SCHEMBL21578056 0.86 PRSS1 (0.50) ELANEPRSS1TMPRSS15KMT2AMEN1
SCHEMBL21578024 0.84 ELANE (0.42) ELANEKMT2AMEN1KDM4EALDH1A1
SCHEMBL20168590 0.83 FOLH1 (0.40) ELANEKMT2AMEN1PPARGFOLH1
SCHEMBL20179228 0.83 FOLH1 (0.39) ELANEKMT2AMEN1PPARGFOLH1
SCHEMBL21577913 0.83 FOLH1 (0.48) PRSS1TMPRSS15FOLH1NPC1SMN1; SMN2
SCHEMBL21577915 0.83 PRSS1 (0.36) PRSS1TMPRSS15KMT2AMEN1FOLH1
SCHEMBL21577924 0.83 PRSS1 (0.38) ELANEPRSS1TMPRSS15FOLH1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2021-11-18 US disclosed
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-13 US disclosed
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2019-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS GPI, TPI1, HPGDS ELANE 919/4885PRSS1 526/4885TMPRSS15 179/4885
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS TPI1, HPGDS, GPI ELANE 1159/4885PRSS1 589/4885TMPRSS15 202/4885
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors GLS, HPGDS, GPI ELANE 715/4885PRSS1 694/4885TMPRSS15 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.